The most often reported of these amendments is the introduction of the option of confidential discounted reimbursement prices for therapies undergoing benefit assessment procedures.
Supporters of confidential pricing had long argued that manufacturers would be willing to offer much greater discounts in Germany if their reimbursement prices could not be publicly accessed and used for international reference pricing (IRP) in countries where Germany is a reference market.
Eventually, this argument persuaded Federal Minister of Health Karl Lauterbach, but pressure from the statutory health insurance (Gesetzliche Krankenversicherung, GKV) meant that the final form of the confidential pricing arrangements in the law was less enticing than might have been hoped.
Order here.
Comments
Post a Comment